{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.4","upperLimit":"94.9","value":"89.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"}],"units":"Participants"}],"description":"The clinical benefit rate was defined as the percentage of participants with a confirmed best response of CR, CRh, PR, CI, and SD by mIWG-MRT-ECNM criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.","id":"OG000","title":"Avapritinib"}],"paramType":"NUMBER","populationDescription":"Response-evaluable Population: all participants who received ≥1 dose of avapritinib, were deemed evaluable per mIWG-MRT-ECNM criteria at baseline as assessed by study steering committee review and had 1 of the following conditions: ≥2 complete postbaseline bone marrow assessments and had been on study for ≥6 cycles; had an end of study visit.","reportingStatus":"POSTED","timeFrame":"Baseline through Month 65","title":"Clinical Benefit Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}